Samsung Biologics has announced the opening of a new office in Tokyo, underscoring its long-term commitment to supporting Japan’s pharmaceutical and biotechnology sectors. The new base will allow the company to collaborate more closely with Japanese partners, offering real-time communication and seamless project management from early development through to commercial manufacturing.

As a leading global contract development and manufacturing organisation (CDMO), Samsung Biologics provides integrated services across the full drug lifecycle. By combining drug substance and drug product capabilities, including sterile filling and lyophilisation, the company delivers faster timelines, reduced risks, and consistent supply reliability. Its flexible manufacturing scale, ranging from small 1 kL runs to 15 kL bioreactors, enables swift tech transfers and tailored production for both emerging biotechs and established pharmaceutical firms.

Backed by one of the world’s largest biologics manufacturing capacities, Samsung Biologics has built a strong track record of regulatory approvals and industry-leading batch success rates. The company is also investing heavily in next-generation modalities such as bispecific antibodies, antibody-drug conjugates, and mRNA therapeutics, ensuring readiness for the future needs of patients worldwide.

The establishment of the Tokyo office reflects Samsung Biologics’ commitment to deepening engagement with the Japanese market, offering proximity, efficiency, and innovation to help its partners bring advanced therapies to patients more quickly and reliably.